Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

DNA Deletion Makes Swedish Chlamydia 'Invisible'
New sequencing and analysis of six strains of Chlamydia will result in improved diagnosis of the sexually transmitted infection. This study provides remarkable insights into a new strain of Chlamydia that was identified in Sweden in 2006 after spreading rapidly across the country by evading most established diagnostic tests.

First Potential Lupus-Specific Treatment In Sight
Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had improvement in overall disease activity without clinically significant flare-ups in one or more isolated organs when compared to patients who received the placebo (inactive agent). The patients receiving BENLYSTA also were able to reduce their intake of steroid medications. The study is the largest ever to be completed for lupus and the first Phase III (late stage) trial of a new biologic immune therapy for lupus to succeed in meeting its primary endpoint and most of its secondary endpoints.
News of the day
Pluronic L-81: A Potential Anti-Diabetic Drug?
Pluronic surfactants are synthetic copolymers based on ethylene oxide and propylene oxide. It has been reported that a nonionic L-81, effectively inhibits absorption of dietary lipids from the intestine and secretion of VLDL and LDL from the liver. Although L-81 is a potent anti-obesity drug, its potential in alleviating obesity-induced insulin resistance and type 2 diabetes has not been fully explored.
Health Insurance

Presidio Pharmaceuticals, Inc. Selects PPI-461 As A Clinical Candidate In Their Hepatitis C Virus NS5A Program

Presidio Pharmaceuticals, Inc. announced that they have selected one of the lead compounds in their hepatitis C virus (HCV) NS5A program to advance toward clinical development. Inhibitors of the HCV NS5A protein are novel and distinct from those currently being pursued by others against the two enzymatic targets of HCV, protease or replicase. With response rates of approximately 50% and tolerance issues associated with standard of care treatments involving the combination of pegylated IFN and ribavirin, there is a clear need for potent, small molecule inhibitors that target multiple viral targets and can be administered orally in future combination therapies. The selected Presidio NS5A inhibitor, PPI-461, exhibits potent and selective activity against all HCV genotypes and showed good oral bioavailability and was well tolerated in animal studies, with elevated liver concentrations relative to serum levels, and potential for once daily dosing in humans. Resistance studies to date suggest that the compound will likely have a high resistance barrier requiring multiple substitutions within the NS5A gene. IND-enabling studies for PPI-461 are currently underway and the Company expects to commence clinical studies in 2010. Additional preclinical research continues on other distinct classes of compounds in the Company"s NS5A program. Presidio Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009